Bone Disorders

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

By July 13, 2018

Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.

USPSTF Issues Recommendation on Screening for Osteoporosis

June 28, 2018

Based on these findings, the USPSTF recommends screening for women aged 65 years and older and in younger women who have been through menopause and are at increased risk.

Treatment of Hidradenitis Suppurativa with SAPHO Syndrome: A Case Review

By June 21, 2018

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

Binge Drinking Tied to Poorer Bone Health in Young Females

June 15, 2018

The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

FDA Approves AI Algorithm That Helps Detect Wrist Fractures

By May 25, 2018

OsteoDetect is a computer-aided detection and diagnostic software that uses an algorithm to analyze 2-D wrist radiographs for signs of distal radius fracture.

Prolia Approved for Glucocorticoid-Induced Osteoporosis

By May 22, 2018

The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).

IV Tramadol Significantly Reduces Post-Op Pain in Phase 3 Study

By May 21, 2018

In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).

Corticosteroid-Related Adverse Events Examined Based on Dose, Duration

By May 14, 2018

Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.

Anxiety Levels Tied to Bone Mineral Density Post-Menopause

May 14, 2018

There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

By May 11, 2018

Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.

Vertebroplasty Does Not Up Pain Relief in Osteoporotic Fracture

May 10, 2018

"Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures," the authors write.

First FDA-Approved Treatment for X-Linked Hypophosphatemia Launched

By April 30, 2018

Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.

Less Pain Post TKA With Addition of Peripheral Nerve Blocks

April 19, 2018

The researchers found that intervention patients reported lower numeric rating scale pain scores on ambulation than the control group on postoperative day (POD) one (1.7 versus 5.0; P <.001).

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By April 17, 2018

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

Pre-Op Chronic Opioid Use Ups Poor Outcomes Post Spinal Fusion

April 02, 2018

The researchers found that 22.3% of patients had documented opioid use for more than 6 months before surgery, and 87.4% of these had continued long-term use postoperatively.

Abaloparatide Followed by Alendronate Ups BMD in Postmenopausal Women

By March 19, 2018

At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.

Year-Long Study Assesses Opioid vs. Non-Opioid Tx for Back, Osteoarthritis Pain

March 07, 2018

The researchers observed no significant difference between the groups in pain-related function over 12 months (overall P=0.58); the mean 12-month Brief Pain Inventory (BPI) interference was 3.4 and 3.3 for the opioid and non-opioid groups, respectively.

Benefits of Rivaroxaban, Aspirin Compared After Hip, Knee Arthroplasty

February 22, 2018

The researchers found that venous thromboembolism occurred in 0.64 and 0.7% of patients in the aspirin and rivaroxaban groups, respectively (difference, 0.06 percentage points; 95% confidence interval [CI], −0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority).

Treating Endothelial Function May Target Root Disease in Marfan Syndrome

February 13, 2018

The researchers found that the MFS/ATR1a-null mice showed unabated aortic root enlargement and remained responsive to losartan, despite being hypotensive and resistant to AngII vasopressor effects.

Does Long-Term ICS Use Increase Fracture Risk in COPD Patients?

By February 05, 2018

Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.

Psychoactive Drug Prescribing Linked to Nursing Facility Hip Fractures

January 29, 2018

In combination, state and facility characteristics explained 6.7% of the variation in hip fracture, and resident characteristics accounted for 7.6% of the variation.

USPSTF Updates Recommendation Statement on Scoliosis Screening

January 10, 2018

"Our review of the current evidence has pointed to more questions than answers about the benefits and harms of screening children and teenagers with no symptoms of scoliosis," said USPSTF member Alex R. Kemper, MD, MPH.

Do Vitamin D, Calcium Supplements Cut Fracture Risk in Older Patients?

By December 26, 2017

Thirty-three randomized trials (n=51,145) were identified that met the inclusion criteria.

Steroid Injection Site Linked to Bone Changes in Osteoarthritis Patients

By November 29, 2017

Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.

Does Inhaled Corticosteroid Use Up the Risk of Fracture in Children?

November 14, 2017

Inhaled corticosteroids are not associated with increased odds of fracture in the pediatric asthma population

USPSTF Issues Recommendations for Osteoporosis Screening

November 08, 2017

Screening for osteoporosis with bone measurement testing should also occur in postmenopausal women <65 years who are at increased risk of osteoporosis as determined by a formal clinical risk assessment tool (B recommendation).

CombiPatch, Minivelle Patches No Longer in Shortage

By October 03, 2017

Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.

Romosozumab Followed by Alendronate Superior in Reducing Fracture Risk

By September 12, 2017

ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.

Fracture Risk Reduced with Abaloparatide Followed by Alendronate

By September 11, 2017

The data showed a statistically significant fracture risk reduction through 3.5 years.